Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 14/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30665623 | 0.96 | MME (0.47) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29351914 | 0.91 | ALDH1A1 (0.50) | SLC7A5CTSDENPEPALDH1A1 | |
| SCHEMBL38651899 | 0.90 | CTSD (0.49) | CTSDBACE1 | |
| SCHEMBL30052478 | 0.88 | ALDH1A1 (0.47) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29453382 | 0.88 | CTSD (0.48) | SLC7A5CTSDENPEPALDH1A1 | |
| SCHEMBL29598573 | 0.88 | ENPEP (0.51) | MMEACECPA1ACE2ENPEP | |
| SCHEMBL9491298 | 0.88 | ALDH1A1 (0.53) | SLC7A5CTSDENPEPALDH1A1 | |
| SCHEMBL9491302 | 0.88 | ALDH1A1 (0.53) | SLC7A5CTSDENPEPALDH1A1 | |
| SCHEMBL16698375 | 0.88 | ALDH1A1 (0.53) | SLC7A5CTSDENPEPALDH1A1 | |
| SCHEMBL14941289 | 0.88 | ALDH1A1 (0.53) | SLC7A5CTSDENPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666988-A | Composition for synthesis Trizepatide and synthetic method of Trizepatide | 深圳佳肽生物科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| CN-118666988-A | Composition for synthesis Trizepatide and synthetic method of Trizepatide | 深圳佳肽生物科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | MME 824/4885ACE 1190/4885CPA1 245/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | MME 105/4885ACE 486/4885CPA1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.